Tibetan veterinary medicine composition and application of Tibetan veterinary medicine composition in treatment of infectious diarrhea of yaks

Abstract

The invention belongs to the field of veterinary drugs, and particularly relates to a Tibetan veterinary drug composition and application of the Tibetan veterinary drug composition in treatment of infectious diarrhea of yaks. The composition comprises nine types of Tibetan veterinary medicinal plants including Geranium tanguticum, Swertia speckled, delphinium, dracocephalum tanguticum, safflower, Sowthistle, trogopterus dung or charred Wuling, licorice, Forsythia suspensa leaf and Scutellaria baicalensis. The Tibetan veterinary drug composition contains antibacterial, anti-inflammatory, antiviral, antiprotozoal and other active components, and shows relatively strong corrosion resistance besides the pharmacological activity, so that the addition of excessive preservatives is avoided, the relatively long storage time is ensured, and the Tibetan veterinary drug composition has dual effects. The medicine components are administered in an oral liquid form to form a safe, efficient, durable and convenient Tibetan veterinary medicine composition, and the Tibetan veterinary medicine composition can be used for treating diarrhea diseases of yaks of different age groups caused by single infection and mixed infection of bacteria, viruses and parasites.

Description

Technical Field

[0001] The invention belongs to the field of veterinary medicines, and in particular relates to a Tibetan veterinary medicine composition and application thereof in treating yak infectious diarrhea. Background Art

[0002] Diarrhea is one of the important restrictive factors that plague the healthy development of yak breeding, and to a certain extent affects the breeding, growth, and meat and milk production of yaks. Frequent chemical drug treatments not only prevent and treat diarrhea, but also cause excessive residues in meat and milk. Excretion of feces and urine into the natural environment will also cause certain ecological pollution, and there are certain public health problems. Developing green and antibiotic-free plant medicines is one of the best ways to effectively avoid the above problems. Tibetan veterinary medicinal plants are widely distributed in plateau areas. Their rich resource advantages play an important role in the healthy development of agriculture and animal husbandry with yaks as the core, and gradually demonstrate incomparable advantages in the process of disease prevention and control. Based on this, this case selected commonly used Tibetan veterinary drugs in the northwestern Sichuan plateau for formulation and compatibility, prepared convenient, stable, and antibiotic-free oral liquid preparations, and evaluated the prevention and treatment effects of yaks with clinical mixed infectious diarrhea, in order to provide reference materials for the prevention and treatment of yak diarrhea. Summary of the invention

[0003] In view of the above problems, the first technical solution of the present application discloses a Tibetan veterinary medicine composition, which comprises the following components by weight:

[0004] Geranium truncatum: 20-30 portions;

[0005] Spotted deer sprouts: 10-15 servings;

[0006] Delphinium spurredum: 10-20 copies;

[0007] Tangut Blue Orchid: 10-30 portions;

[0008] Safflower: 10-15 parts;

[0009] Curly silk gesneriaceae: 15-25 portions;

[0010] Wulingzhi or Wulingtan: 10-15 parts;

[0011] Licorice: 10-20 parts;

[0012] Forsythia Leaf and Scutellaria Baicalensis: 10-25 parts.

[0013] Preferably, by mass, it comprises the following components:

[0014] Geranium chinense: 25 parts;

[0015] Spotted deer sprouts: 15 servings;

[0016] Delphinium spicatum: 20 copies;

[0017] Tangut Blue Orchid: 15 parts;

[0018] Safflower: 10 parts;

[0019] Curly silk gesneriaceae: 15 portions;

[0020] Wulingzhi or Wulingtan: 10 parts;

[0021] Licorice: 15 parts;

[0022] Forsythia Leaf and Scutellaria Baicalensis: 20 parts.

[0023] The second technical solution of the present application discloses the use of the above-mentioned Tibetan veterinary medicine composition in the treatment of mixed infectious diarrhea in yaks.

[0024] Furthermore, the Tibetan medicine composition is administered in the form of an oral liquid.

[0025] The third technical solution of the present application discloses a method for preparing a Tibetan medicine composition oral liquid, comprising the following steps:

[0026] soaking and decocting the Tibetan veterinary medicine composition to obtain a medicinal liquid;

[0027] Anhydrous ethanol is added to the drug solution, and the solution is allowed to stand, and the supernatant is concentrated by rotary evaporation, and the pH value is adjusted to 7.0-7.4 to obtain the product.

[0028] Furthermore, the amount of anhydrous ethanol added is such that the final alcohol content of the drug solution is 75%.

[0029] Furthermore, the rotary evaporation is concentrated to a final concentration of 1-2 g / mL.

[0030] And, the Tibetan medicine composition oral liquid prepared according to the above preparation method and its application in treating mixed infectious diarrhea in yaks.

[0031] The present invention has the following beneficial effects: the Tibetan veterinary medicine composition for treating infectious diarrhea in yaks comprises 9 kinds of Tibetan veterinary medicinal plants, namely, Geranium gansuensis, Swertia speckledum, Delphinium saccharum, Orchidaceae tangutica, Carthamus tinctorius, Gesneria serrata, Aconitifolia charcoal, Licorice, Forsythiae suspensa and Scutellaria baicalensis. The proportion of the composition is determined according to the principle of "monarch-minister-adjuvant-envoy", and the medicine is crushed, sieved, decocted and packaged, and safety evaluation and clinical trial research are carried out at the same time. The Tibetan veterinary medicine composition contains active components such as antibacterial, anti-inflammatory, antiviral and antiprotozoal. In addition to the above-mentioned pharmacological activities, it also exhibits strong antiseptic properties, thereby avoiding the addition of too much preservative to ensure a longer storage time, and has dual effects. The drug components are administered in the form of oral liquid, forming a safe, efficient, durable and convenient Tibetan veterinary medicine composition, which can be used to treat yak diarrhea of ​​different ages caused by single infection and mixed infection of bacteria, viruses and parasites. DETAILED DESCRIPTION

[0032] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0033] Unless otherwise specifically stated, the numerical expressions and numerical values ​​of the steps set forth in these embodiments do not limit the scope of the application. The technology and methods known to those of ordinary skill in the relevant art may not be discussed in detail, but in appropriate cases, the technology and methods should be considered as a part of the authorization specification. In all examples shown and discussed here, any specific value should be interpreted as being merely exemplary, rather than as a limitation. Therefore, other examples of exemplary embodiments can have different values.

[0034] In response to the above problems, the first embodiment of the present application discloses a Tibetan veterinary medicine composition, which includes the following components in parts by mass: 20-30 parts of Geranium glycyrrhiza; 10-15 parts of Spotted Deer Sprout; 10-20 parts of Delphinium sacrum; 10-30 parts of Tangut Orchid; 10-15 parts of Carthamus tinctorius; 15-25 parts of Gesneria volvacea; 10-15 parts of Notopterygium wilfordii or Notopterygium wilfordii charcoal; 10-20 parts of Licorice; 10-25 parts of Forsythia suspensa and Scutellaria baicalensis.

[0035] Preferably, the following components are included by mass: 25 parts of Geranium gansuensis; 15 parts of spotted deer sprouts; 20 parts of Delphinium spurredum; 15 parts of Tangut blue orchid; 10 parts of safflower; 15 parts of cissus tanguticus; 10 parts of safflower; 15 parts of cissus convolvulus; 10 parts of truncatum or charcoal; 15 parts of licorice; 20 parts of forsythia leaf and scutellaria baicalensis.

[0036] In the present embodiment, the above Tibetan medicine composition determines the composition ratio according to the "monarch-minister-assistant-envoy" formula, wherein: Geranium glycyrrhizae, Orchid tanguticum, and Gesneria volvacea are monarch medicines, which mainly play an antidiarrheal effect, and their composition ratios are 20-30 parts, 10-30 parts, and 15-25 parts, respectively; Delphinium sacchariflorum, Forsythia suspensa and Scutellaria baicalensis are ministerial medicines, which assist the monarch medicine to reduce inflammation and relieve pain, and their composition ratios are 10-20 parts and 10-25 parts, respectively; Swertia spotted, Carthamus tinctorius, and Aconiti Lateralis Preparata are adjuvants, which mainly have the effects of promoting blood circulation and dispersing blood stasis, and their composition ratios are all 10-15 parts; Licorice is used as a harmonizing medicine to alleviate the above-mentioned main toxic and side effects, and their composition ratios are 15-20 parts, respectively. The above-mentioned Tibetan veterinary medicine composition contains active ingredients such as antibacterial, anti-inflammatory, antiviral, and antiprotozoal, and can be used to treat diarrhea in yaks of different ages caused by single and mixed infections of bacteria, viruses, and parasites. At the same time, it exhibits strong preservative properties, thereby avoiding the addition of preservatives and ensuring a longer storage time.

[0037] The second embodiment of the present application discloses the use of the above-mentioned Tibetan veterinary medicine composition in the treatment of mixed infectious diarrhea in yaks. The Tibetan medicine composition is administered in the form of oral liquid, which is safer, more efficient, longer-lasting and more convenient.

[0038] The third embodiment of the present application discloses a method for preparing a Tibetan medicine composition oral liquid, comprising the following steps:

[0039] soaking and decocting the Tibetan veterinary medicine composition to obtain a medicinal liquid;

[0040] Anhydrous ethanol is added to the drug solution, and the solution is allowed to stand, and the supernatant is concentrated by rotary evaporation, and the pH value is adjusted to 7.0-7.4 to obtain the product.

[0041] In this embodiment, the soaking and decoction of the Tibetan medicine composition is a conventional Chinese medicinal material decoction method, and this application does not make any special restrictions. It only provides a preferred method of adding deionized water to the above-mentioned Tibetan medicine composition at a ratio of 1:15 and soaking it for 40 minutes; boiling it in a ceramic Chinese medicine pot over high heat until it boils, then switching to low heat and continuing to decoct for 45 minutes, after filtering the medicinal liquid, adding deionized water at a ratio of 1:5 and repeating the decoction once according to the above steps, combining the two filtrates and concentrating them to a certain volume using a rotary evaporator.

[0042] In this embodiment, the purpose of standing anhydrous ethanol is to fully remove the protein, polysaccharide and mucus components in the combined extract. The standing time is preferably 12 hours. After that, the supernatant is taken and the ethanol is recovered by rotary evaporation using a rotary evaporator until there is no alcohol taste, and rotary evaporation is continued to the final concentration of 1g / mL.

[0043] In this embodiment, the pH value is preferably adjusted using 40% sodium hydroxide and 1 mol / L hydrochloric acid solution.

[0044] It should be noted that, in order to ensure the quality of the drug solution, Tween-80 and stevioside may be added to the drug solution prepared in the present application to increase the drug solubility and flavor correction function, so as to adjust the taste of the drug solution and extend the preservation time.

[0045] And, the Tibetan medicine composition oral liquid prepared according to the above preparation method and its application in treating yak infectious diarrhea.

[0046] The Tibetan veterinary medicine composition of the present application and its efficacy will be described below through specific examples.

[0047] Example 1 Preparation of Tibetan veterinary medicine oral liquid

[0048] Weigh 250g of Geranium ganqingensis, 150g of Tangut Qinglan, 150g of Gesneria tanguticola, 200g of Delphinium scapularis, 200g of Scutellaria baicalensis, 150g of Swertia punctata, 100g of Carthamus tinctorius, 100g of Pentaxylus aconitifolius, and 150g of Licorice respectively. Add 21.75 liters of deionized water at a ratio of 1:15 and soak for 40 minutes. Boil in an automatic stainless steel decoction machine until boiling, then continue to boil for 45 minutes over low heat. After filtering the liquid, add 7.25 liters of deionized water at a ratio of 1:5, and repeat the above steps for 1 decoction. Combine the two filtrates and concentrate to a certain volume using a rotary evaporator. The concentrated drug solution was added with anhydrous ethanol by volume until the final alcohol content was 75%, and after being fully mixed and allowed to stand overnight, the supernatant was filtered out, and the ethanol was recovered by rotary evaporator until there was no alcohol taste, and the drug solution was concentrated to a final concentration of 1g / mL, and the pH value was adjusted to about 7.0-7.4 with 40% sodium hydroxide and 1mol / L hydrochloric acid solution, and 0.2% Tween-80 and 0.5% stevioside were added according to the volume ratio according to the amount of the concentrated solution. Finally, the drug solution was divided into 100mL polypropylene plastic bottles and sterilized at 100℃ for 15min before use.

[0049] Example 2 Determination of the antiseptic efficacy of oral liquid composition

[0050] Experimental method: Take 5 portions of the oral solution (1 g / mL) of Example 1 on day 0, day 30, and day 90, respectively, and prepare Sabouraud agar medium containing different concentration gradients (0.5, 0.25, and 0.125 g / mL). 5 -10 6 The culture medium was coated with the bacterial solution of Aspergillus niger CICC 2487 at CFU / mL and the colony count was recorded after culturing at 25°C for 5 days. The preservative efficacy was evaluated by the reduction multiple of the colony count.

[0051] Experimental results: As shown in Table 1, it can be seen that the oral liquid of the composition has a strong disinfecting ability (preservative effect) against Aspergillus niger CICC 2487.

[0052] Table 1 Determination of the antiseptic ability of the oral liquid composition against Aspergillus niger CICC 2487

[0053]

[0054] Example 3 Evaluation of the antibacterial activity of oral liquid composition in vitro

[0055] The in vitro anti-Escherichia coli standard strain ATCC25922 and Staphylococcus aureus ATCC25923 activity was evaluated by the broth microdilution method. The specific operation is as follows: Take 2 96-well plates, add 100 μL of MH broth to each well, add 100 μL of the combined oral solution (original concentration of 1 g / mL) to each well of the 1st column, rows 1-4, and add 100 μL of 512 μg / mL doxycycline solution to each well of the 1st column, rows 5-8 as a control. Dilute the combined oral solution in multiple proportions to the 11th column, and move the last 100 μL of liquid to the 12th column. Finally, add 100 μL of the solution diluted to 10 in each well of the 1st to 11th columns of the two 96-well plates. 5 -10 6 CFU / mL of Escherichia coli standard strain ATCC25922 and Staphylococcus aureus ATCC25923. The minimum inhibitory concentration (MIC) was recorded after culturing at 37°C for 12-16 hours.

[0056] Experimental results: As shown in Table 2, it can be seen from the table that the MICs of the oral liquid of the combination against the standard strains of Escherichia coli ATCC25922 and Staphylococcus aureus ATCC25923 are 15.625 mg / mL and 7.8125 mg / mL, respectively, and the antibacterial effect against Staphylococcus aureus is better than that against Escherichia coli.

[0057] Table 2 MIC of oral solution of composition (unit: μg / mL or mg / mL)

[0058]

[0059] Example 4 Evaluation of viral activity in vitro of oral liquid composition

[0060] 1. The blocking effect of the oral liquid of the combination on viruses

[0061] The oral solution of the composition of Example 1 was diluted from the maximum concentration of 0.8 times (0.8 g / mL) into 3 dilutions, added to a 96-well plate where cells had grown into a monolayer, 100 μL per well, and 3 replicates for each dilution. After 4 h at 37°C, the solution was discarded, and then 100 TCID 50 100 μL of virus solution was carefully discarded after culturing at 37°C for 2 hours. After washing the plate twice with PBS, maintenance solution was added to each well. Cell control wells, solvent control wells, virus control wells and blank control wells were set up. The wells were cultured in a 37°C 5% CO2 incubator and the cell cytopathic effect (CPE) was observed daily. When the CPE of the virus control wells reached 70% to 80%, the activity was determined by the MTT method. 50 μL of MTT solution was added to each well 4 hours before the determination. Then the culture solution was carefully discarded and the OD value was determined by a microplate reader after adding DMSO. The virus inhibition rate and the half inhibitory concentration (IC 50) was used as an index for screening effective anti-BRVA drugs. Inhibition rate (%) = (OD value of drug treatment group - OD value of virus control group) / (OD value of cell control group - OD value of virus control group) × 100%.

[0062] 2. The inhibitory effect of the oral liquid of the combination on viruses

[0063] 100TCID 50 Inoculate the virus into a 96-well plate that has grown into a monolayer of cells, 100 μL per well, and culture at 37°C for 2 hours. Discard the liquid, wash the plate, and add 100 μL / well of the pre-diluted drug at 3 dilutions. Set up 3 replicates as well as cell control, solvent control, virus control wells, and blank control wells. Culture in a 37°C 5% CO2 incubator for 4 hours, aspirate the culture medium, wash twice with PBS, and continue to culture with maintenance solution. When the CPE of the virus control well reaches 70% to 80%, the MTT method is used to determine the activity in the same way as in 1.6.1.

[0064] 3. Virus-killing effect of oral liquid of the combination

[0065] The three dilutions of the composition were mixed with an equal volume of 100 TCID 50 After the virus solution was mixed at 37°C for 4 hours, it was added to a 96-well cell culture plate covered with a monolayer of cells, 100 μL per well, and 3 replicates for each dilution. Cell control, solvent control, virus control and blank control wells were also set up. The wells were cultured in a 37°C 5% CO2 incubator for 2 hours, the culture medium was aspirated, the wells were washed twice with PBS, and the maintenance solution was added to continue the culture. When the CPE of the virus control wells reached 70% to 80%, the activity was determined by the MTT method in the same way as in Example 4.1.

[0066] Experimental results: As shown in Table 3, it can be seen from the table that the oral liquid of the combination showed a certain blocking effect, inhibitory effect and killing effect on BRVA, and its IC 50 The concentrations of 1 mg / mL and 1 mg / mL of 1 mg / mL and 1 mg / mL of 3 mg / mL and 4.6 mg / mL of 1 mg / mL and 1.37, 1.10 and 7.17 respectively. The results of the three modes of action showed that the oral solution of the combination had the strongest killing effect on BRVA.

[0067] Table 3 Inhibition rate and IC of BRVA 50 and TI

[0068]

[0069] Note: A, B, and C are three gradient concentrations under safe concentrations.

[0070] Example 5 Determination of the anticoccidial index (ACI) of the oral liquid of the composition

[0071] To avoid contamination by coccidian oocysts, make the following preparations: clean and disinfect the chicken house before bringing in the chicks to kill any remaining eggs; disinfect and dry the chicken cages, bedding nets, manure trays, etc.; treat feed troughs and waterers in the same way; wear shoe covers and lab coats when entering the chicken house to prevent bringing in coccidian and bacterial infections in the chicks.

[0072] Preparation of coccidian oocysts: Sporulated oocysts of commercial Eimeria tenella were used to infect 7-day-old chicks for in vivo passage. Feces were collected on the 6th to 8th day after infection, and the oocysts were separated and purified by saturated saline flotation method. The oocysts were placed in a 2.5% potassium dichromate solution and sporulated for 48 hours at 28°C under aerobic conditions. The sporulation rate of the oocysts was calculated under a McMaster counting plate microscope (the sporulation rate of the oocysts in the infection test should be greater than 80%), and stored at 4°C for later use.

[0073] Feeding and grouping: After the introduction of 1-day-old chicks, pay attention to keeping warm (about 30℃), provide sufficient drinking water (pre-warmed), and feed a fixed number and quantity. At 14 days of age, they were randomly divided into 3 different treatment groups (10 per group) and raised in different chicken cages. The specific grouping and dosing are shown in Table 4.

[0074] Table 4 Chick grouping and treatment design

[0075]

[0076] Infection and treatment: Coccidia oocysts were inoculated at 15 days of age. The chicks were weighed and numbered before inoculation, and the weight was recorded. Sporulated oocysts of Eimeria tenella (dosage of 5.0×10 4 The drug was administered on the third day after inoculation of coccidia oocysts, and the drug-treated groups were continuously administered for 3 days, while the healthy and infected control groups were not administered.

[0077] Indicator observation and statistics

[0078] (1) Survival rate: After inoculation of oocysts, the health status of the chickens was observed every day, the mortality of each group was recorded, and the survival rate was calculated.

[0079] (2) Fecal oocyst count: 5-8 days after inoculation of oocysts, collect 2g of fecal sample every day for oocyst count, which is used as the average oocyst yield. Use a McMaster counting plate to count coccidia oocysts in feces (OPG, the number of coccidia oocysts per gram of feces). The specific method is as follows: Place the fecal sample in a clean 100mL beaker, first add 10mL of saturated sodium chloride solution, crush and mix with a glass rod, then add 50mL of saturated sodium chloride solution, filter with a 60-mesh sieve immediately after mixing, then immediately aspirate the filtrate to fill 2 counting chambers, let it stand on the microscope stage for 3-5 minutes, and count under a 10x objective.

[0080] (3) Relative weight gain rate: On the 8th day after infection with oocysts, weigh the chickens and record the data. According to the initial and final weights of the chickens in each group, calculate the average weight gain rate, and calculate the relative weight gain rate according to the following formula (Relative weight gain rate = average weight gain of the infected control group or the infected drug-treated group / average weight gain of the healthy control group * 100%).

[0081] (4) Lesion score: On the 8th day after infection with oocysts, slaughter the whole chicken, take out the cecum and cut it longitudinally, observe the cecal wall lesions and the condition of the contents, and perform cecal lesion scoring (when the lesions on both sides of the cecum are inconsistent, take the more severe side as the standard). The lesion score is divided into five grades from 0 to 4, and the specific criteria are as follows:

[0082] Grade 0: The cecal contents are normal, and there are no visible lesions on the intestinal wall with the naked eye.

[0083] Grade 1: The cecal contents are normal, the intestinal wall is not thickened, and there are a few scattered ecchymotic patches (lesions).

[0084] Grade 2: The cecal contents are significantly bloody, the intestinal wall is thickened, and there are more ecchymotic patches (lesions).

[0085] Grade 3: There is a large amount of blood or cecal core (blood clot or grayish-white caseous banana-shaped mass) in the cecum, and the intestinal wall is thickened, deformed or atrophied.

[0086] Grade 4: There is a blood clot or cecal core in the cecum, and the intestinal wall is extremely thickened or significantly atrophied; chicks that died of coccidiosis are all counted as grade 4.

[0087] (5) Relative oocyst production (ROP): Calculate the average oocyst production of each group of chickens from 5 to 8 days after inoculation with oocysts, and calculate the relative oocyst production (ROP) of the healthy control group and each infected drug-treated group according to the following formula. ROP = average ROP of the healthy control group or the infected drug-treated group / average ROP of the infected control group.

[0088] (6) Anticoccidial index (ACI): ACI = (relative weight gain rate + survival rate) - (lesion value + oocyst value), where the lesion value = average lesion score * 10, and the conversion of the oocyst value is shown in Table 5.

[0089] Table 5 Conversion relationship between relative oocyst production (%) and oocyst value

[0090]

[0091] Judge the efficacy of the anticoccidial drug according to the anticoccidial index (ACI), and the judgment criteria are as follows: (High efficacy: ACI > 180; Medium efficacy: 160 < ACI ≤ 180; Low efficacy: 120 < ACI ≤ 160; Ineffective: ACI ≤ 120).

[0092] Experimental results: as shown in Table 6, the oral liquid of the combination is equivalent to diclazuril, with ACI indexes of 160.79 and 161.13 respectively, and has moderate anticoccidial activity.

[0093] Table 6 Chick grouping and treatment design

[0094]

[0095] Example 6 Clinical treatment trial of weaned yaks

[0096] 1. Clinical treatment trial of weaned yaks

[0097] Experimental method: 26 weaned yaks (weight range 19.27+1.25Kg) with diarrhea were selected and randomly divided into the experimental group and the control group, and treated with the oral liquid of the composition and the control drug respectively. The composition was decocted in water, and each yak was orally administered 25mL (containing 25g of crude drug) / time, twice / day, for 5 consecutive days; gentamicin sulfate injection, intramuscular injection, 1mL (0.01g) / kg, twice / day, for 5 consecutive days;

[0098] It should be noted that this medication method is aimed at the weaned yaks (calves) of the present applicant. In the specific implementation process, when actually using the drug for yaks of different age stages, taking into account factors such as the grazing conditions of the yaks and the convenience of medication, each calf is given one bottle (25mL) every two days, and an adult yak is given one bottle (25mL) per day, with the drug given once in the morning and evening each day. The number of days for medication is determined to be 5-7d according to the condition of the disease.

[0099] 2. Clinical prevention trial of diarrhea in weaned yaks

[0100] Experimental method: 26 weaned yaks with natural diarrhea were selected and randomly divided into the experimental group and the control group, and the combination was decoctioned and normal saline was used respectively. The combination was decoctioned and 25 mL (containing 25 g of crude drug) was administered orally, twice a day, for 5 consecutive days; the control group was given normal saline. The occurrence of diarrhea during the medication period and within 3 days after the medication was stopped was observed, and the protection rate was calculated.

[0101] 3. Growth promotion test

[0102] Experimental method: 44 healthy weaned yaks were selected and randomly divided into an experimental group and a blank control group, with 22 yaks in each group. The experimental group was treated with the same medication as in 1.8.1 for 21 consecutive days; the blank control group did not add any medication. The incidence of diarrhea in weaned yaks during the medication period was observed, and the feed intake and body weight at the beginning of the experiment, on the 7th, 14th and 21st days of the experiment were recorded.

[0103] The experimental results are shown in Table 7 (clinical treatment results of the oral liquid of the combination on weaned yaks), Table 8 (clinical prevention results of the oral liquid of the combination on weaned yaks), and Table 9 (experimental results of the oral liquid of the combination on growth promotion of weaned yaks). It can be seen that the oral liquid of the combination has a curative effect on weaned yaks, and its cure rate is greater than that of gentamicin (Table 7). The oral liquid of the combination has a good preventive and therapeutic effect of 84.61% (Table 8), and has a certain growth-promoting effect (Table 9).

[0104] Table 7 Clinical treatment results of oral liquid of the composition on weaned yaks

[0105]

[0106] Table 8 Clinical preventive treatment results of oral liquid of the combination on weaned yaks

[0107]

[0108] Table 9 Effect of oral liquid composition on growth promotion of weaned yaks

[0109]

[0110] Note: “-” means no drug is added.

[0111] The above results show that the oral liquid preparation of the composition of the present invention can effectively prevent and treat diarrhea in weaned yaks, while improving their feed intake and growth performance.

[0112] The above embodiments are only used to illustrate the technical solutions of the present invention, but the protection scope of the present invention is not limited thereto. The embodiments of the present invention and the features in the embodiments can be arbitrarily combined with each other without conflict. Any technician familiar with the technical field can easily think of changes or replacements within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A Tibetan veterinary medicine composition, characterized in that: By mass, it includes the following components: Geranium truncatum: 20-30 portions; Spotted deer sprouts: 10-15 servings; Delphinium spurredum: 10-20 copies; Tangut Blue Orchid: 10-30 portions; Safflower: 10-15 parts; Curly silk gesneriaceae: 15-25 portions; Wulingzhi or Wulingtan: 10-15 parts; Licorice: 10-20 parts; Forsythia Leaf and Scutellaria Baicalensis: 10-25 parts.

2. The Tibetan medicine composition according to claim 1, characterized in that: By mass, it includes the following components: Geranium chinense: 25 parts; Spotted deer sprouts: 15 servings; Delphinium spicatum: 20 copies; Tangut Blue Orchid: 15 parts; Safflower: 10 parts; Curly silk gesneriaceae: 15 portions; Wulingzhi or Wulingtan: 10 parts; Licorice: 15 parts; Forsythia Leaf and Scutellaria Baicalensis: 20 parts.

3. Use of the Tibetan veterinary medicine composition according to claim 1 or 2 in treating and preventing infectious diarrhea in yaks and improving their growth performance.

4. The application according to claim 4, characterized in that: The Tibetan medicine composition is administered in the form of oral liquid.

5. A method for preparing a Tibetan medicine composition oral liquid, characterized in that: The following steps are involved: soaking and decocting the Tibetan veterinary medicine composition to obtain a medicinal liquid; Anhydrous ethanol is added to the drug solution, and the solution is allowed to stand, and the supernatant is concentrated by rotary evaporation, and the pH value is adjusted to 7.0-7.4 to obtain the product.

6. The preparation method according to claim 3, characterized in that: The amount of anhydrous ethanol added is such that the final alcohol content of the drug solution is 75%.

7. The preparation method according to claim 3, characterized in that: The rotary evaporation concentration is carried out to a final concentration of 1-2 g / mL.

8. The Tibetan medicine composition oral liquid prepared according to any one of the preparation methods of claims 5-7.

9. Use of the Tibetan medicine composition oral liquid according to claim 8 in treating and preventing infectious diarrhea in yaks and improving their growth performance.

Images